Filtered By:
Drug: Minocycline

This page shows you your search results in order of date. This is page number 6.

Order by Relevance | Date

Total 88 results found since Jan 2013.

Minocycline-associated vasculitis of extracranial branches of vertebral arteries presenting as myelopathy
Vasculitis limited to extracranial vasculature is rare and has not been reported in association with anti-neutrophil cytoplasmic antibodies (ANCA) or minocycline. Here we report such a case.
Source: Neurology Neuroimmunology and Neuroinflammation - May 15, 2014 Category: Neurology Authors: Garg, N., Altowaijri, G. H., Nesbit, G. M., Gultekin, S. H., Bourdette, D. N. Tags: All Cerebrovascular disease/Stroke, All Spinal Cord Clinical/Scientific Notes Source Type: research

Minocycline mitigates motor impairments and cortical neuronal loss induced by focal ischemia in rats chronically exposed to ethanol during adolescence.
MINOCYCLINE MITIGATES MOTOR IMPAIRMENTS AND CORTICAL NEURONAL LOSS INDUCED BY FOCAL ISCHEMIA IN RATS CHRONICALLY EXPOSED TO ETHANOL DURING ADOLESCENCE. Brain Res. 2014 Mar 14; Authors: Oliveira GB, Fontes EA, de Carvalho S, da Silva JB, Fernandes LM, Oliveira MC, Prediger RD, Gomes-Leal W, Rodrigues Lima R, Maia CS Abstract Ethanol is an important risk factor for the occurrence of cerebral ischemia contributing to poor prognosis and inefficacy of drug treatments for stroke-related symptoms. Females have a higher lifetime risk for stroke than males. Moreover, female gender has been associated with increased...
Source: Brain Research - March 14, 2014 Category: Neurology Authors: Oliveira GB, Fontes EA, de Carvalho S, da Silva JB, Fernandes LM, Oliveira MC, Prediger RD, Gomes-Leal W, Rodrigues Lima R, Maia CS Tags: Brain Res Source Type: research

Targeting Microglial Activation in Stroke Therapy: Pharmacological Tools and Gender Effects.
Abstract Ischemic stroke is caused by critical reductions in blood flow to a part of brain or spinal cord. Microglia are the resident immune cells of the central nervous system, and they respond to stroke by assuming an activated phenotype that releases cytotoxic cytokines, reactive oxygen species, proteases, and other factors. This acute, innate immune response may be teleologically adapted to limit infection, but in stroke this response can exacerbate injury by further damaging or killing nearby neurons and other cell types and by recruiting infiltration of circulating cytotoxic immune cells. The microglial resp...
Source: Current Medicinal Chemistry - December 28, 2013 Category: Chemistry Authors: Chen Y, Won SJ, Xu Y, Swanson RA Tags: Curr Med Chem Source Type: research

Minocycline Repurposing in Critical Illness: Focus on Stroke.
Abstract Stroke is a devastating disease associated with high morbidity and mortality. Despite the approved indication of systemic thrombolytic therapy in the United States for the acute management of ischemic stroke, its use is limited given a strict eligibility criteria and a risk for hemorrhagic transformation as a feared adverse effect. Many agents have been studied without success for neuroprotection in patients with stroke to reduce vascular injury and improve long-term functional outcomes. Minocycline is a tetracycline antibiotic that shows promise for its neuroprotective effects in multiple animal models a...
Source: Current Topics in Medicinal Chemistry - September 20, 2013 Category: Chemistry Authors: Vivian Liao T, C Forehand C, Hess DC, Fagan SC Tags: Curr Top Med Chem Source Type: research

Intravenous Minocycline in Acute Stroke: A Randomized, Controlled Pilot Study and Meta-analysis Clinical Sciences
Conclusions— In this pilot study of a small sample of acute stroke patients, intravenous minocycline was safe but not efficacious. The study was not powered to identify reliably or exclude a modest but clinically important treatment effect of minocycline. Larger trials would improve the precision of the estimates of any treatment effect of minocycline. Clinical Trial Registration— URL: http://www.anzctr.org.au. Unique identifier: ACTRN12612000237886.
Source: Stroke - August 26, 2013 Category: Neurology Authors: Kohler, E., Prentice, D. A., Bates, T. R., Hankey, G. J., Claxton, A., van Heerden, J., Blacker, D. Tags: Acute Cerebral Hemorrhage, Acute Cerebral Infarction, Neuroprotectors, Other Stroke Treatment - Medical Clinical Sciences Source Type: research

Monitoring Neuroprotective Effects Using Positron Emission Tomography With 11CITMM, a Radiotracer for Metabotropic Glutamate 1 Receptor Basic Sciences
Conclusions— [11C]ITMM-PET may be a useful technique for characterizing the change in mGlu1 level during the occurrence and progression of neuronal damage and for evaluating the neuroprotective effects of drugs after ischemia.
Source: Stroke - August 26, 2013 Category: Neurology Authors: Yui, J., Xie, L., Fujinaga, M., Yamasaki, T., Hatori, A., Kumata, K., Nengaki, N., Zhang, M.-R. Tags: PET and SPECT Basic Sciences Source Type: research

Emerging experimental therapies for intracerebral hemorrhage: targeting mechanisms of secondary brain injury.
This article reviews the pathophysiology of secondary brain injury relevant to ICH, examines pertinent experimental models, and highlights emerging therapeutic strategies. Treatment paradigms discussed include thrombin inhibitors, deferoxamine, minocycline, statins, granulocyte-colony stimulating factors, and therapeutic hypothermia. Despite promising experimental and preliminary human data, further studies are warranted prior to effective clinical translation. PMID: 23634928 [PubMed - in process]
Source: Neurosurgical Focus - May 1, 2013 Category: Neurosurgery Authors: Belur PK, Chang JJ, He S, Emanuel BA, Mack WJ Tags: Neurosurg Focus Source Type: research

Preservation of Motor Function After Spinal Cord Ischemia and Reperfusion Injury Through Microglial Inhibition ORIGINAL ARTICLES: ADULT CARDIAC
Conclusions Minocycline limits microglial activation, paralleling functional preservation after aortic cross-clamping. These data suggest functional microglia contribute to reperfusion injury after spinal cord ischemia. The effects of minocycline demonstrate a potential pharmacological therapy as well as demonstrating a potential cellular target in preventing paraplegia after aortic intervention.
Source: The Annals of Thoracic Surgery - April 30, 2013 Category: Cardiovascular & Thoracic Surgery Authors: Smith, P. D., Bell, M. T., Puskas, F., Meng, X., Cleveland, J. C., Weyant, M. J., Fullerton, D. A., Reece, T. B. Tags: Cerebral protection ORIGINAL ARTICLES: ADULT CARDIAC Source Type: research

Involvement of matrix metalloproteinases‐2 and ‐9 in the formation of a lacuna‐like cerebral cavity
We used a modified pial vessel disruption (PVD) protocol with adult male Wistar rats to mimic small‐vessel stroke in the cerebral cortex. Within 3 weeks, this lesion develops into a single lacuna‐like cavity, which is fluid‐filled and encapsulated by reactive astrocytes. Minocycline treatment that commences 1 hr after lesion and continues for 6 days prevents the cavitation and causes a filling of the lesion with reactive astrocytes and no barrier. Here, we determined whether inhibition of matrix metalloproteinases‐2 and ‐9 (MMPs) mediates this minocycline action. Confocal microscopy revealed increased punctate st...
Source: Journal of Neuroscience Research - April 22, 2013 Category: Neuroscience Authors: Francisco S. Cayabyab, Krishnamoorty Gowribai, Wolfgang Walz Tags: Research Article Source Type: research

Targets of vascular protection in acute ischemic stroke differ in type 2 diabetes
The objective of the present study was to determine the effects of acute manipulation of potential targets for vascular protection [i.e., NF-B, peroxynitrite, and matrix metalloproteinases (MMPs)] on vascular injury and functional outcome in a diabetic model of cerebral ischemia. Ischemia was induced by middle cerebral artery occlusion in control and type 2 diabetic Goto-Kakizaki rats. Treatment groups received a single dose of the peroxynitrite decomposition catalyst 5,10,15,20-tetrakis(4-sulfonatophenyl)prophyrinato iron (III), the nonspecific NF-B inhibitor curcumin, or the broad-spectrum MMP inhibitor minocycline at re...
Source: AJP: Heart and Circulatory Physiology - March 15, 2013 Category: Cardiology Authors: Kelly-Cobbs, A. I., Prakash, R., Li, W., Pillai, B., Hafez, S., Coucha, M., Johnson, M. H., Ogbi, S. N., Fagan, S. C., Ergul, A. Tags: VASCULAR BIOLOGY AND MICROCIRCULATION Source Type: research

Effects of Minocycline Plus Tissue Plasminogen Activator Combination Therapy After Focal Embolic Stroke in Type 1 Diabetic Rats Basic Sciences
Conclusions— Combination therapy with minocycline plus tPA may be beneficial in ameliorating inflammation and reducing infarction, brain swelling, and hemorrhage after ischemic stroke with diabetes mellitus/hyperglycemia.
Source: Stroke - February 25, 2013 Category: Neurology Authors: Fan, X., Lo, E. H., Wang, X. Tags: Animal models of human disease, Type 1 diabetes, Acute Cerebral Infarction, Embolic stroke, Thrombolysis Basic Sciences Source Type: research

Targets of Vascular Protection in Acute Ischemic Stroke Differ in Type 2 Diabetes.
The objective of the current study was to determine the effects of acute manipulation of potential targets for vascular protection (i.e., NFkB, peroxynitrite, and matrix metalloproteinases) on vascular injury and functional outcome in a diabetic model of cerebral ischemia. Ischemia was induced by middle cerebral artery occlusion in control and type 2 diabetic Goto-Kakizaki rats. Treatment groups received a single dose of peroxynitrite decomposition catalyst FeTPPs,a non-specific NFkB inhibitor curcumin, or a broad-spectrum matrix metalloproteinase (MMP) inhibitor minocycline at reperfusion. Post-stroke infarct volume, edem...
Source: American Journal of Physiology. Heart and Circulatory Physiology - January 18, 2013 Category: Physiology Authors: Kelly-Cobbs AI, Prakash R, Li W, Pillai B, Hafez S, Coucha M, Johnson MH, Ogbi SN, Fagan SC, Ergul A Tags: Am J Physiol Heart Circ Physiol Source Type: research

Tetracyclines and neuromuscular disorders.
Abstract Tetracyclines are a class of antibiotics which could act as neuroprotective molecules in several neurological disorders, such as Huntington disease, Parkinson disease, stroke and multiple sclerosis. The main biological effects of tetracyclines are the inhibition of microglial activation, the attenuation of apoptosis and the suppression of reactive oxygen species production. The anti-apoptotic effect of tetracyclines involves the mitochondrion, and the major target for neuroprotective effects of tetracyclines lies within the complex network that links mitochondria, oxidative stress and apoptosis.Neuromuscu...
Source: Current Neuropharmacology - June 1, 2012 Category: Drugs & Pharmacology Authors: Orsucci D, Mancuso M, Filosto M, Siciliano G Tags: Curr Neuropharmacol Source Type: research